Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuli Ding

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Plant Cell|October 10, 2020
Diverse Roles of the Salicylic Acid Receptors NPR1 and NPR3/NPR4 in Plant ImmunityYanan Liu, Tongjun Sun, Yulin Sun, et al.
Cancer Communications (London, England)|October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trialsJian Li, Ting Deng, Yanhong Gu, et al.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
The Lancet. Respiratory Medicine|December 1, 2025
Glecirasib plus sitneprotafib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trialJia Zhong, Jun Zhao, Jianchun Duan, et al.
Nature Medicine|January 6, 2025
Glecirasib in KRAS<sup>G12C</sup>-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Jian Fang, Ligang Xing, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Plant Cell|October 10, 2020
Diverse Roles of the Salicylic Acid Receptors NPR1 and NPR3/NPR4 in Plant ImmunityYanan Liu, Tongjun Sun, Yulin Sun, et al.
Cancer Communications (London, England)|October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trialsJian Li, Ting Deng, Yanhong Gu, et al.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
The Lancet. Respiratory Medicine|December 1, 2025
Glecirasib plus sitneprotafib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trialJia Zhong, Jun Zhao, Jianchun Duan, et al.
Nature Medicine|January 6, 2025
Glecirasib in KRAS<sup>G12C</sup>-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Jian Fang, Ligang Xing, et al.
Pageof 2